Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) was downgraded by research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Thursday.

Other analysts have also recently issued reports about the company. Zacks Investment Research raised Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.25 price target for the company in a report on Wednesday. Stifel Nicolaus raised Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and raised their price target for the company from $8.00 to $15.00 in a report on Wednesday, July 26th. HC Wainwright assumed coverage on Tetraphase Pharmaceuticals in a report on Tuesday, July 11th. They issued a “buy” rating and a $15.00 price target for the company. BMO Capital Markets reissued a “buy” rating and issued a $12.00 price target on shares of Tetraphase Pharmaceuticals in a report on Monday, May 15th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Tetraphase Pharmaceuticals in a report on Thursday, July 27th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $10.65.

Tetraphase Pharmaceuticals (TTPH) traded down 0.18% during mid-day trading on Thursday, hitting $5.44. The stock had a trading volume of 144,256 shares. The stock has a 50-day moving average price of $7.12 and a 200 day moving average price of $6.95. The firm’s market cap is $277.73 million. Tetraphase Pharmaceuticals has a 12-month low of $3.11 and a 12-month high of $9.93.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.76) by $0.07. The business had revenue of $1.59 million during the quarter, compared to analyst estimates of $1.54 million. Tetraphase Pharmaceuticals had a negative net margin of 2,092.20% and a negative return on equity of 79.79%. The firm’s quarterly revenue was up 28.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.47) earnings per share. Equities analysts anticipate that Tetraphase Pharmaceuticals will post ($2.55) EPS for the current fiscal year.

WARNING: This article was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.dailypolitical.com/2017/08/10/bidaskclub-downgrades-tetraphase-pharmaceuticals-inc-nasdaqttph-to-sell.html.

Several hedge funds have recently bought and sold shares of TTPH. UBS Group AG boosted its stake in Tetraphase Pharmaceuticals by 2.3% in the first quarter. UBS Group AG now owns 17,269 shares of the biopharmaceutical company’s stock valued at $159,000 after buying an additional 387 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its stake in Tetraphase Pharmaceuticals by 0.7% in the second quarter. Schwab Charles Investment Management Inc. now owns 129,681 shares of the biopharmaceutical company’s stock valued at $925,000 after buying an additional 874 shares in the last quarter. Teza Capital Management LLC boosted its stake in Tetraphase Pharmaceuticals by 8.9% in the first quarter. Teza Capital Management LLC now owns 15,650 shares of the biopharmaceutical company’s stock valued at $144,000 after buying an additional 1,281 shares in the last quarter. American International Group Inc. boosted its stake in Tetraphase Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 22,390 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 1,486 shares in the last quarter. Finally, Citadel Advisors LLC boosted its stake in Tetraphase Pharmaceuticals by 18.6% in the first quarter. Citadel Advisors LLC now owns 15,924 shares of the biopharmaceutical company’s stock valued at $146,000 after buying an additional 2,496 shares in the last quarter. 35.76% of the stock is owned by institutional investors and hedge funds.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.